Costs for selected strategies, discounted cost/case prevented and cost/QALY gained compared to no testing and last (non-dominated) strategy
| Strategy | Total cost of strategy per 10,000 people living with HIV | Cases TB prevented (discounted) | QALYs gained compared to no testing (discounted) | Cost/case averted | Cost/QALY compared to no testing | Incremental cost/QALY compared to last strategy |
|---|---|---|---|---|---|---|
| BHIVA 2011 | £749,274 | 2.28 | 1.28 | £21,371 | £37,952 | EXTENDED DOMINANCE |
| TST in BA | £749,660 | 3.9 | 2.09 | £12,566 | £23,429 | £23,429 |
| TST in BA and MI | £761,797 | 4.49 | 2.43 | £13,614 | £25,218 | EXTENDED DOMINANCE |
| NICE 2011 | £788,037 | 1.11 | 0.63 | £78,429 | £139,281 | DOMINATED |
| IGRA in BA | £812,048 | 6.83 | 3.85 | £16,314 | £28,971 | EXTENDED DOMINANCE |
| IGRA in BA and MI | £865,959 | 9.06 | 5.1 | £18,250 | £32,410 | EXTENDED DOMINANCE |
| IGRA in all | £1,056,702 | 10.17 | 5.72 | £35,030 | £62,209 | EXTENDED DOMINANCE |
| NICE 2016 | £1,058,522 | 10.17 | 5.72 | £35,234 | £62,571 | DOMINATED |
| TST&IGRA in all | £1,219,154 | 10.99 | 5.88 | £47,166 | £88,139 | EXTENDED DOMINANCE |
| TST&IGRA&CXR&IS in all | £1,999,789 | 20.58 | 10.44 | £63,142 | £124,393 | EXTENDED DOMINANCE |
BA - Black African, BHIVA – British HIV Association, CXR – chest X ray, IGRA – Interferon-gamma release assay, IS – induced sputum, MI – middle [TB] incidence countries, NICE – National Institute of Health and Care Excellence, QALY – Quality adjusted life year, TB – tuberculosis (includes active disease and subclinical tuberculosis cases), TST – tuberculin skin test.